Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
3D Printers for Specialists - 2Red Crescent: More than 100,000 civilian structures damaged in Iran
- 3Antimatter took to the road for the very first time. Here’s why it matters
- 4Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
- 5NASA releases new photos of interstellar comet 3I/ATLAS
- Artemis II astronauts will see parts of the moon no human has before. Here’s how
- US students studying housing, health outcomes and sustainability win 2026 Rhodes scholarships
- Well known Worldwide Caf\u00e9s to Experience
- Volunteers aiding humpback whale stranded in Baltic get death threats
- Remains of banker missing since 1999 found on California beach by family looking for seashells
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients
- Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- Bruno Mars tour 2026: How to get tickets for 'The Romantic Tour,' presale times, prices and more
